Aptose Biosciences Balance Sheet Health
Financial Health criteria checks 3/6
Aptose Biosciences has a total shareholder equity of $-2.9M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $13.0M and $15.9M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$9.25m |
| Equity | -US$2.90m |
| Total liabilities | US$15.89m |
| Total assets | US$12.99m |
Recent financial health updates
Recent updates
Aptose Biosciences Q2 2022 Earnings Preview
Aug 01Aptose Biosciences Continues To Drift Without Thesis-Changing Data
Jul 19Aptose Deep In The Doghouse Due To Lack Of Pipeline Progress
Feb 02Aptose: High Risk, High Reward. Watch Its Phase I Studies
Aug 05Aptose Biosciences (APTO) Presents Corporate Update at EHA 2021 - Slideshow
Jun 18Aptose Biosciences: An Assessment
Apr 27Aptose Shares Sell Off As The Market Wanted More Than Further Signs And Portents
Dec 08Aptose Shares Look Undervalued Ahead Of Value-Driving Efficacy Data
Nov 12Financial Position Analysis
Short Term Liabilities: APTO has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: APTO has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: APTO is debt free.
Reducing Debt: APTO's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: APTO has sufficient cash runway for 2 months based on last reported free cash flow, but has since raised additional capital.
Forecast Cash Runway: APTO is forecast to have sufficient cash runway for 2 months based on free cash flow estimates, but has since raised additional capital.